September 8, 2016
Cambridge, MA

Solid Observes World Duchenne Awareness Day

On Wednesday, September 7, 2016, Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.

The event convened many of those impacted by the disease - patients, families, industry, researchers, healthcare providers and local policy representatives - to show unity in finding a cure for Duchenne muscular dystrophy and demonstrate that innovation takes unfailing drive and commitment. It also celebrated Cambridge as a center of innovation in Duchenne muscular dystrophy.

Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day 2016.

With the great city of Boston as a backdrop, the group came together and raised red lanterns along the Charles River, honoring those with Duchenne muscular dystrophy and celebrating hope for the future.

Follow the event on Twitter #WDAD16 and #DuchenneCambridge.

Related news

Jun26

Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities

Jun18

We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.

Jun18

- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET

May19

- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

May10
Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial
Apr18

Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial

Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Mar14

Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.

Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

Pages

More information about Solid?

Please subscribe to receive our latest news